Biotechnology
Commented by André Will-Laudien on November 27th, 2024 | 07:00 CET
Biotech in focus! The 2025 blockbusters: Pfizer, BioNTech, Nyxoah, Valneva or Evotec - Who will take off?
The Q3 figures have now been processed. In the shadow of the tech giants on the Nasdaq, biotech stocks are currently being neglected. However, it is important to note that as pressure on the international economies increases, so does the likelihood of interest rate cuts by the central banks. Many investors have been underweight in biotech for quarters, prioritizing other sectors. All of this could be reversed in 2025. An early positioning with the most important protagonists seems promising. We are picking the best opportunities for you from the "Advent calendar."
Read
Commented by André Will-Laudien on November 25th, 2024 | 07:00 CET
Takeovers – The 200% opportunities for 2025! Speculate now on the turnaround for Evotec, BioNxt, Bayer and Nel ASA!
The DAX 40 index is going from strength to strength, following the huge wave of buying since the US election. High-tech and defense stocks are leading the charge. Contrary to this positive trend, biotech stocks have so far been ignored. However, since interest rates are likely to be lowered for the foreseeable future due to the weakening economy, the time of the research-intensive life sciences industry will soon return. There are takeover rumors about Evotec. BioNxt is currently undervalued, and Bayer should be among the winners next year after successful restructuring efforts. It is worth taking a closer look.
Read
Commented by Juliane Zielonka on November 21st, 2024 | 07:15 CET
Bayer, BioNxt Solutions, BioNTech – Patents and acquisitions for market penetration
Three companies in the pharmaceutical industry are pursuing different strategies to strengthen their market position: Bayer is making targeted investments in the Japanese heart medication market and acquiring the rights to a promising active ingredient for treating heart muscle diseases for up to EUR 560 million. BioNxt Solutions is developing an innovative form of medication delivery for drugs to treat the incurable disease of multiple sclerosis - with an absolute focus on patients. The biotech company is thus securing patent protection in key international markets. BioNTech, in turn, is massively expanding into the Asian oncology market with the USD 800 million acquisition of the Chinese company Biotheus. All three companies are expanding their positions in lucrative future markets. Which strategy will be successful?
Read
Commented by Fabian Lorenz on November 20th, 2024 | 08:15 CET
Takeover battle and soaring profits! Evotec, Bayer, Saturn Oil + Gas
A bombshell announcement came from Evotec late last week. US biotech company Halozyme Therapeutics is offering EUR 11 per Evotec share. Evotec was not informed in advance and seems to be preparing to fend off the takeover. Analysts believe the share price has moved far away from its fundamental value. So, should investors sell the stock now? Experts suggest investors should buy shares of Saturn Oil & Gas. The mid-sized oil producer from Canada is expected to be among the winners under the upcoming Trump administration and will likely soon be paying an attractive dividend. The stock has clear catch-up potential. Meanwhile, analysts are significantly reducing the target price for Bayer. Is there a chance of a turnaround at the agricultural and pharmaceutical giant?
Read
Commented by Armin Schulz on November 20th, 2024 | 07:00 CET
Evotec, Nyxoah, Bayer – A lot of excitement in the healthcare industry
The healthcare sector is currently abuzz with activity. Evotec is the focus of a potential takeover by the US company Halozyme, which has caused the shares of the German biotech company to skyrocket. At the same time, the Belgian medical technology company Nyxoah expects to receive FDA approval soon for its Genio system for the treatment of sleep apnea, which would pave the way for its market entry in the US. Bayer, on the other hand, disappointed with its latest quarterly figures, which showed a significant decline in revenue and EBITDA, leading to a slide in its share price. We take a closer look at these three companies.
Read
Commented by Stefan Feulner on November 19th, 2024 | 07:00 CET
Novo Nordisk, BioNxt Solutions, Bavarian Nordic – Opportunities after a horror week
The past trading week was one to forget for the biotech and medtech sectors. With the nomination of the anti-vaccine Robert F. Kennedy as the future US Secretary of Health, stocks such as Moderna, Pfizer and BioNTech lost disproportionately. Even the broadly diversified Nasdaq Biotech Index closed with a weekly loss of over 10%. However, many analysts see the sudden slide as an attractive entry opportunity.
Read
Commented by Fabian Lorenz on November 18th, 2024 | 07:00 CET
Takeover speculation and momentum: BioNTech, Rheinmetall, Vidac Pharma
BioNTech aims to strengthen its cancer-fighting pipeline by acquiring the Chinese biotech firm Biotheus. The Mainz-based company is laying out up to USD 950 million for the company, which specializes in the development of therapies for cancer and autoimmune diseases. This is the latest example of takeovers in the cancer sector. Vidac Pharma, with a market capitalization of just over EUR 30 million, appears to be favorably valued. Analysts share this view, as Vidac is working on a revolutionary cancer therapy. While Vidac's share price jumped in the second half of the year, Rheinmetall consolidated. Will the defense stock be able to break out with the tailwind from Trump?
Read
Commented by André Will-Laudien on November 14th, 2024 | 07:15 CET
The acquisition carousel is gaining momentum! Evotec, Vidac Pharma, BioNTech, and Formycon in focus
The biotech sector is in the spotlight again today. Triton's entry into Evotec means that another deal is in the works, and investors should now take notice. Many still remember MorphoSys, where there were short-term gains of up to 400% at the beginning of the year. Before that, the stock had been trading with high volumes. Will Formycon or Vidac Pharma be next on the list? Formycon is now getting significantly more attention because the stock switched to the Prime Standard. Evotec has once again disappointed operationally, yet the value has increased by a good 50% in just two months. Those who analyze carefully can profit again. A sharp analytical eye is worthwhile.
Read
Commented by Fabian Lorenz on November 14th, 2024 | 07:00 CET
SHARE PRICES EXPLODE as biotech stocks rise! BioNTech, Evotec, Nyxoah
Is Evotec about to make a quick turnaround? A financial investor is positioning itself for a potential takeover, and the stock surged significantly in the last days. Does this mean that the disappointment over the quarterly figures has been forgotten? Could Nyxoah's stock be the next to skyrocket? The chances of this are good. The medtech company expects FDA approval for the first quarter of 2025 and aims to roll out its main product across the US market next year. Analysts see billion-dollar potential, rapidly increasing revenues, and a favourable P/E ratio. BioNTech shares are also benefiting from a rating upgrade by renowned analysts. The target price has been raised significantly. Could this help the German biotech leader break out of its recent consolidation phase?
Read
Commented by André Will-Laudien on November 13th, 2024 | 07:30 CET
Gold correction - Now is the time to take advantage of the lows! Takeover rumors at Evotec, Desert Gold, Bayer and SMCI
The re-election of Donald Trump as US President had varying effects on the capital markets. The US dollar gained against all currencies, while the hot topic Bitcoin reached new all-time highs of over USD 90,000. The enormous influx of funds into the US stock markets initially slowed down other exchanges. At the same time, the previously sought-after precious metals corrected sharply, putting pressure on mining stocks again. The first shockwaves have now been absorbed, and attention is turning to the real political issues that the White House will now push forward. Defense, industry, and security are in the spotlight, while biotech and green tech remain sidelined. There are some interesting special movements that we will examine here.
Read